Accessibility Menu
Ixico Plc logo

Ixico Plc(LSE) IXI

Current Price£0.08
Market Cap£18.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-86%
5 Year-88%
1 Year-19%
1 Month+1%
Ixico Plc last closing stock price
MetricPriceDate
Last closeGBX 8.502026-07-23
Ixico Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.03%GBX 8.252026-07-16
1 month+0.59%GBX 8.452026-06-23
3 month+21.43%GBX 7.002026-04-24
Year to date-27.66%GBX 11.752025-12-31
1 year-19.05%GBX 10.502025-07-23
3 year-57.5%GBX 20.002023-07-24
5 year-87.59%GBX 68.502021-07-23
Since inception-85.59%GBX 0.592013-10-15

Ixico Plc Financials at a Glance

Market Cap

£18.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£13.71M

Net Income (TTM)

-£3.36M

EPS (TTM)

-£0.02

P/E Ratio

-4.34

Dividend

£0.00

Beta (Volatility)

-0.01 (Low)

Price

£0.08

Volume

6,598

Open

£0.09

Previous Close

£0.08

Daily Range

£0.08 - £0.08

52-Week Range

£0.06 - £0.15

Estimated Earnings Date

Dec 8, 2026

IXI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ixico Plc

IXICO plc is a London-based company specializing in data analytics services for the biopharmaceutical industry. Established in 1995, IXICO supports clinical trials by managing the entire lifecycle of study-generated data, focusing on neurological disorders.

Products and Services
  • Data analytics for clinical trials, including study design and project management
  • Proprietary technology platforms like Assessa and TrialTracker
  • Expert consultancy and post-market surveillance support
Growth Outlook
  • Focus on neurological disorders positions IXICO in a growing market
  • Recent partnerships enhance capabilities in clinical trial management
  • Expansion into international markets supports long-term growth potential
Financial Highlights
  • Recent quarterly revenue of £3.95 million, showing a 19% increase from the previous quarter
  • Cash and cash equivalents of £1.68 million, providing liquidity for operations
  • Current ratio of 2.83 indicates strong short-term financial health
IXICO plc operates in a niche market with a focus on neurological disorders, which are increasingly recognized for their complexity and need for specialized data analytics. The company's proprietary technology platforms, Assessa and TrialTracker, streamline clinical trial processes, enhancing efficiency and accuracy. Recent financial performance indicates a positive trend, with a notable increase in quarterly revenue, reflecting growing demand for IXICO's services. The strong current ratio suggests that the company is well-positioned to meet its short-term obligations, providing a solid foundation for future growth. As IXICO continues to expand its international presence and forge new partnerships, it remains a compelling option for investors interested in the biotechnology sector.
AI Generated • Jul 15, 2026

Industry

Life Sciences Tools and Services

CEO

Bram Goorden

Website

ixico.com

Headquarters

London, GL EC1A 9PN, GB

IXI Financials

Key Financial Metrics (TTM)

Gross Margin

48.26%

Operating Margin

-35.66%

Net Income Margin

-24.98%

Return on Equity

-16.18%

Return on Capital

-21.24%

Return on Assets

-13.99%

Earnings Yield

-23.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£18.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

218.97M

Volume

6.60K

Avg. Volume

100.99K

Financials (TTM)

Gross Profit

£6.66M

Operating Income

-£4.61M

EBITDA

-£3.36M

Operating Cash Flow

-£2.72M

Capital Expenditure

-£182.00K

Free Cash Flow

-£2.91M

Cash & ST Invst.

£1.68M

Total Debt

£559.00K

Ixico Plc Performance Analysis

Ixico Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-09-30GBP 8,643,000-6.0%
20232023-09-30GBP 6,665,000-22.9%
20242024-09-30GBP 5,766,000-13.5%
20252025-09-30GBP 6,534,00013.3%
Ixico Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-3027.2%
Q22025-03-31-0.6%
Q42025-09-303.7%
Q22026-03-3118.7%
Ixico Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-09-30GBP 0.02-32.3%
20232023-09-30GBP -0.02N/A
20242024-09-30GBP -0.0469.7%
20252025-09-30GBP -0.02-55.6%
Ixico Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-09-3058.2%
Q22025-03-319.0%
Q42025-09-3032.4%
Q22026-03-31-61.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£3.95M

+55.6%

Gross Profit

£2.01M

+97.3%

Gross Margin

50.95%

N/A

Market Cap

£18.61MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£235.61K

N/A

Employees

79

N/A

Net Income

-£1.12M

+20.5%

EBITDA

-£987.00K

+26.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£1.68M

-33.8%

Total Debt

£559.00K

+73.1%

Accounts Receivable

£3.43M

+140.8%

Inventory

£0.00

N/A

Long Term Debt

£449.00K

+115.9%

Short Term Debt

£110.00K

-52.2%

Return on Assets

-13.99%

N/A

Return on Invested Capital

-23.20%

N/A

Free Cash Flow

-£1.39M

-16.0%

Operating Cash Flow

-£1.27M

-8.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ABDX.LAbingdon Health Plc
£0.10-2.56%
FAB.LFusion Antibodies plc
£0.11+1.40%
TRX.LTissue Regenix Group plc
£0.07+0.00%
NFX.LNuformix plc
£0.00+1.89%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$212.25+0.02%
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
INTCIntel
$102.85-0.02%

Questions About IXI

What is the current price of Ixico Plc?

Ixico Plc is trading at £0.08 per share.

What is the 52-week range for Ixico Plc?

Over the past 52 weeks, Ixico Plc has traded between £0.06 and £0.15.

How much debt does Ixico Plc have?

As of the most recent reporting period, Ixico Plc reported total debt of £179.00K.

How much cash does Ixico Plc have on hand?

Ixico Plc reported £3.54M in cash and cash equivalents in its most recent financial results.

What is Ixico Plc’s dividend yield?

Ixico Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.